PFM
ENGN icon

Privium Fund Management’s enGene Therapeutics ENGN Stock Holding History

Privium Fund Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.4M Hold
352,087
– – 0.5% 32
2025
Q4 		$3.18M Buy
+352,087
New +$2.82M 0.59% 26

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Privium Fund Management's ENGN Position: Q1 2026 in Review

Privium Fund Management held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 352,087 shares worth $2.4M. The position accounts for 0.5% of the portfolio, ranked #32.

Privium Fund Management first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.18M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Privium Fund Management held 352,087 shares of enGene Therapeutics worth $2.4M as of Q1 2026.
  • Privium Fund Management left its enGene Therapeutics share count unchanged in Q1 2026.
  • enGene Therapeutics made up 0.5% of Privium Fund Management's portfolio in Q1 2026, its #32 holding.
  • Privium Fund Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Privium Fund Management's enGene Therapeutics position peaked at $3.18M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.